Stockreport

CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial

CERo Therapeutics Holdings, Inc.  (CERO) 
PDF Trial advancing with ongoing safety and pharmacologic evaluation and planned expansion into MDS and MF SOUTH SAN FRANCISCO, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- [Read more]